U.S. Personal Products Stock News

Procter & Gamble (PG) has kicked off 2026 with a flurry of brand activity, including the new Head & Shoulders BARE Itchy Scalp Relief Serum, upgraded scalp care collections, a Cascade Clean Machine tour and Native’s microsoap series, The Golden Pear Affair. See our latest analysis for Procter & Gamble. All this brand activity comes as Procter & Gamble’s share price sits at US$161.21, with a 30 day share price return of 11.77% and a 90 day share price return of 9.17%. The 1 year total...

Setting the scene for Meta Platforms after a mixed year of returns Meta Platforms (META) enters today’s session after a mixed performance, with a 1 day and past week decline, a gain over the past month and 3 years, and a lower total return over the past year. See our latest analysis for Meta Platforms. At a share price of US$649.81, Meta’s recent 1 day and 7 day share price declines sit against a modest 90 day share price return of 6.62% and a very strong 3 year total shareholder return of...

Phillips Edison & Company, Inc. recently reported past fourth-quarter and full-year 2025 results showing higher revenue of US$187.86 million and net income of US$47.53 million for the quarter, and issued 2026 guidance targeting net income per share between US$0.74 and US$0.77. An interesting aspect of this update is that management’s 2026 outlook includes Same-Center NOI growth of 3.8%, aligned with its stated long-term 3% to 4% range, suggesting confidence in the underlying performance of...

If you are wondering whether Viking Therapeutics is attractively priced or already reflects a lot of optimism, starting with a clear view of its valuation can help frame your next move. The stock last closed at US$30.49, with returns of 16.0% over the past 7 days, a 0.7% decline over 30 days, a 13.9% decline year to date, a 3.4% gain over 1 year and a very large 3 year gain, and a 5 year gain of just over 3x. Recent news flow around Viking Therapeutics has mainly focused on its drug...

Addus HomeCare recently announced it released its fourth-quarter and full-year 2025 results on February 23, 2026, followed by a management conference call and webcast on February 24 to discuss performance and outlook with investors. What stands out is how this earnings release coincides with growing attention on the company’s Personal Care operations, where reimbursement changes and acquisition activity have become central to its business profile. Next, we’ll examine how expectations around...

Aurora Innovation (AUR) just paired its latest quarterly results and widened full year loss with a major step forward in commercial driverless trucking on US public roads and an employee focused shelf registration. See our latest analysis for Aurora Innovation. At a share price of US$4.22, Aurora’s recent 7-day share price return of 11.64% contrasts with its 1-month share price return decline of 8.06% and a 1-year total shareholder return decline of 55.20%. This suggests short term momentum...

Huntington Ingalls Industries has recently reported higher fourth-quarter and full-year 2025 revenue and net income, completed builder’s sea trials for the John F. Kennedy (CVN 79) aircraft carrier, and confirmed a quarterly dividend of US$1.38 per share payable on March 13, 2026. Together with strong reliability data for its REMUS 100 autonomous underwater vehicle and a new collaboration with Path Robotics on physical AI in manufacturing, these updates highlight how HII is coupling...

If you are wondering whether Entegris is priced for opportunity or already reflecting high expectations, it helps to start by looking at how the market has been treating the stock recently and how that lines up with its fundamentals. Entegris shares last closed at US$130.90, with returns of 18.6% over 7 days, 28.2% over 30 days, 46.2% year to date, 20.8% over 1 year, 52.2% over 3 years and 30.6% over 5 years. Recent price moves sit against a backdrop of ongoing interest in semiconductor...

Why Kohl's (KSS) is back on investors' radar Kohl's (KSS) is drawing fresh attention as investors reassess the retailer's recent share performance alongside its current earnings profile, with US$15.8b in revenue and US$195 million in net income on the books. See our latest analysis for Kohl's. The recent 7 day share price return of 6.77% and 90 day share price return of 12.96% contrast with a 30 day share price return of 7.62% and year to date share price return of 11.34%. A 66.21% total...

If you are wondering whether Celsius Holdings at around US$44.39 is still reasonably priced or already running ahead of itself, you are not alone. The stock has pulled back recently, with a 7.5% decline over the last week and a 15.6% decline over the last 30 days, even though the 1 year return stands at 95.9%. Recent coverage has focused on Celsius Holdings as a high growth consumer brand in the energy drinks space, with attention on its distribution partnerships and expanding shelf presence...

Plains All American Pipeline (NasdaqGS:PAA) is drawing fresh attention as a high-yield dividend stock after a shift in interest rate expectations. Robust US employment data has led the Federal Reserve to signal that interest rate cuts could be delayed. This changing rate outlook is putting more focus on income ideas, with PAA's dividend profile now featuring more prominently in investor discussions. Plains All American Pipeline operates in the midstream energy space, with assets focused on...

Enterprise Products Partners (EPD) is back on investors’ radar after reporting fourth quarter results featuring record natural gas inlet and NGL fractionation volumes, higher operating margins, and another increase in its quarterly distribution. See our latest analysis for Enterprise Products Partners. The recent earnings beat, completion of a US$1.44b buyback program, and another distribution increase have come alongside a 9.5% 1 month share price return and a 136.3% 5 year total shareholder...

Why GE HealthCare Technologies (GEHC) is on investors’ radar GE HealthCare Technologies (GEHC) has drawn attention after recent share price moves, including a one-month return of about a 7% decline and a past 3 months gain of roughly 8%, raising questions about how its fundamentals line up. See our latest analysis for GE HealthCare Technologies. At a share price of US$78.65, GE HealthCare Technologies has seen a 7.22% 1 month share price decline after a 7.52% 3 month share price return. The 1...

Investors are facing fresh scrutiny of Cytokinetics (NasdaqGS:CYTK) as a formal investigation looks at potential fiduciary duty breaches by certain directors and officers. The inquiry focuses on an alleged omission of a required Risk Evaluation and Mitigation Strategy from the New Drug Application for aficamten. This omission reportedly led to a three month delay in FDA approval, raising questions about governance, disclosure practices and regulatory oversight at the company. Cytokinetics,...

AllianceBernstein Holding (AB) is back in focus after updating investors on January assets under management, which reached US$875b following a 1% month over month move, along with recent earnings showing lower quarterly and full year net income. See our latest analysis for AllianceBernstein Holding. The recent January assets under management update and the latest earnings arrive after a choppy few weeks for the units, with a 7 day share price return of a 4.34% decline, contrasting with a 6.8%...

Cushman & Wakefield (NYSE:CWK) has recently added several senior leaders across key U.S. markets and service lines. New appointments include Gabrielle Harvey and Brendan Callahan in Boston, Kevin Donner in Los Angeles, Damla Gerhart for the Midwest Region, and Gregg Metcalf as Executive Director. These moves expand the firm’s capabilities in tenant representation, portfolio services, capital markets, and regional operations. For investors watching NYSE:CWK, these leadership changes arrive...

If you are wondering whether Cigna Group's current share price lines up with its underlying worth, you are in the right place for a clear valuation walkthrough. Cigna Group recently closed at US$287.61, with returns of 1.1% over the past 7 days, 5.8% over 30 days, 3.0% year to date, and a 2.1% decline over the last year, plus returns of 1.5% over 3 years and 52.9% over 5 years. This mix of short term gains and a softer 1 year return has refocused attention on what investors are paying for...

Green Plains has begun Carbon Capture and Sequestration operations, targeting the low carbon fuel market. The company is starting to benefit from related tax credits tied to these CCS activities. Management is also working on asset sales and debt restructuring to reshape the balance sheet. For investors watching NasdaqGS:GPRE, these moves come with the stock at $13.92 and a mixed performance record. The shares are up 10.0% over the past week, 24.2% over the past month, and 35.4% year to...

Opera (OPRA) raised its revenue outlook for the fourth quarter and full year 2025, while also highlighting strong user and transaction growth in its MiniPay stablecoin wallet across emerging markets. See our latest analysis for Opera. Even with the MiniPay momentum and higher 2025 revenue outlook, Opera’s recent share price performance has been weak, with a 30 day share price return of an 8.62% decline and a 1 year total shareholder return of a 41.06% loss, contrasting with a 3 year total...

United Therapeutics recently completed its Phase 3 TETON-1 trial of inhaled treprostinil in idiopathic pulmonary fibrosis, a double-blind, placebo-controlled 52-week study assessing whether the drug can slow lung function decline. This milestone, building on earlier TETON-2 findings, could be pivotal for expanding the Tyvaso franchise into IPF and informing potential regulatory filings. Next, we’ll examine how completing the TETON-1 Phase 3 IPF trial could reshape United Therapeutics’...

Anterix (ATEX) has just put out its Q3 2026 scorecard, with the latest reported quarter in the data set showing revenue of US$1.6 million and basic EPS of US$2.86, alongside trailing 12 month EPS of US$5.13 on net income of US$95.6 million that includes a one off gain of US$141.8 million. Over the past few reported periods, revenue has stayed in a tight band between roughly US$1.4 million and US$1.6 million per quarter, while basic EPS has moved from losses in early 2025 to positive readings...

Clearway Energy recently reached a new three-year high, reflecting strong technical momentum and renewed investor interest in its clean energy business and income profile. This renewed focus on Clearway’s sizeable dividend is particularly important for investors seeking a combination of long-term infrastructure exposure and regular cash distributions. Next, we’ll explore how this recent momentum, anchored by Clearway’s dividend appeal, interacts with the existing investment narrative and...

In early February 2026, AMETEK, Inc. reported record fourth-quarter and full-year 2025 results, issued earnings and sales guidance for 2026, and earlier this month it approved a 10% increase in its quarterly cash dividend to US$0.34 per share, payable on March 31, 2026 to shareholders of record on March 16, 2026. The combination of higher earnings, strong cash generation, upbeat guidance and a higher indicated annual dividend of US$1.36 per share underlines management’s confidence in the...

Why the DAMAC agreement matters for Cognizant Technology Solutions (CTSH) Cognizant Technology Solutions (CTSH) has drawn fresh attention after signing a three year agreement with DAMAC Group, taking on broad responsibility for DAMAC's IT infrastructure, applications, and AI focused digital transformation efforts. See our latest analysis for Cognizant Technology Solutions. The DAMAC news comes after a sharp pullback, with a 1 day share price return showing a 7.16% decline and a 30 day share...